Lead Product(s): Tomivosertib,Anti PD1/PD-L1 therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
In a Phase 2 study, open-label study, tomivosertib demonstrated antitumor activity in combination with checkpoint inhibitors (CPI) in patients with solid tumors who progressed on CPI treatment.